---
title: "Decisiones Estratégicas que Definen el Camino de una Biotecnológica hacia la Clínica: El First-in-Human se Gana Mucho Antes de Empezar"
description: "Las decisiones estratégicas tempranas definen si una biotecnológica llega al first-in-human sin problemas. Aprende cómo las decisiones regulatorias, de CMC y de calidad en la UE/RU determinan el éxito."
url: https://qbdgroup.com/es/blog/decisiones-estrategicas-definen-camino-biotecnologica-first-in-human
type: "Artículo del blog"
language: es
published: 2026-02-04
author: "Angeles Escartí-Nebot"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"Decisiones Estratégicas que Definen el Camino de una Biotecnológica hacia la Clínica: El First-in-Human se Gana Mucho Antes de Empezar\", https://qbdgroup.com/es/blog/decisiones-estrategicas-definen-camino-biotecnologica-first-in-human"
---
# Decisiones Estratégicas que Definen el Camino de una Biotecnológica hacia la Clínica: El First-in-Human se Gana Mucho Antes de Empezar
> Las decisiones estratégicas tempranas definen si una biotecnológica llega al first-in-human sin problemas. Aprende cómo las decisiones regulatorias, de CMC y de calidad en la UE/RU determinan el éxito.

## Una hoja de ruta práctica para el desarrollo biotecnológico

## En resumen

En conjunto, estos principios destacan una realidad sencilla: el éxito de la entrada en la clínica se configura mucho antes de que se administre la dosis al primer sujeto. Los desarrolladores que abordan estas cuestiones con antelación no solo alcanzan el first-in-human, sino que llegan *preparados, creíbles y en posición de progresar con confianza*.

[Hablemos de cómo podemos apoyar a tu equipo.](https://info.qbdgroup.com/en/contact)

![Emerging Biotech Solutions - CTA](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/blog-images/blog_posts/content/early-biotech-strategy-first-in-human-eu-uk/Emerging_20Biotech_20Solutions_20-_20CTA.jpg)

#### Referencias

European Medicines Agency (EMA)Scientific Advice and Protocol AssistanceGuidance on early dialogue with regulators to optimise development plans and reduce regulatory uncertainty.

European Medicines Agency (EMA)PRIME: Priority MedicinesFramework supporting enhanced interaction and early engagement for medicines addressing unmet medical needs.

European Medicines Agency (EMA)Orphan Designation and IncentivesOverview of orphan designation criteria, protocol assistance, and regulatory incentives in the EU.

European Commission. DG SANTEClinical Trials Regulation (EU) No 536/2014Legal framework governing clinical trials in the EU, including harmonised assessment and the Clinical Trials Information System (CTIS).

European Medicines Agency (EMA)Clinical Trials Information System (CTIS)Practical guidance on submission, assessment, and transparency requirements under the Clinical Trials Regulation.

International Council for Harmonisation (ICH)ICH Q8(R2) – Pharmaceutical DevelopmentGuidance on systematic development approaches and understanding of product and process design.

International Council for Harmonisation (ICH)ICH Q9(R1) – Quality Risk ManagementFramework for identifying, evaluating, and controlling quality risks throughout the product lifecycle.

International Council for Harmonisation (ICH)ICH Q10 – Pharmaceutical Quality SystemModel for an effective quality system applicable across the product lifecycle.

International Council for Harmonisation (ICH)ICH Q11 – Development and Manufacture of Drug SubstancesGuidance on CMC development strategies and documentation expectations for regulatory submissions.

European Federation of Pharmaceutical Industries and Associations (EFPIA)Clinical Trials Regulation and EU Clinical Research CompetitivenessIndustry perspective on implementation challenges and strategic implications of CTR and CTIS.

European Innovation Council (EIC)EIC Accelerator ProgrammeFunding and investment support for high-risk, high-impact innovation, including biotech development and scale-up.
---
Source: https://qbdgroup.com/es/blog/decisiones-estrategicas-definen-camino-biotecnologica-first-in-human — © QbD Group. Quote freely with attribution and a link back.